Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma

Head and Neck

Volumn 35, Issue 6, 2013, Pages 809-818

  Thomas, Fabienne ^a,b   Delmar, Paul ^c   Vergez, Sébastien ^a   Rochaix, Philippe ^a,b   Hennebelle, Isabelle ^a,b   McLoughlin, Patricia ^c   Benlyazid, Adil ^b   Sarini, Jérôme ^b   Delord, Jean Pierre ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

early clinical response; erlotinib; HNSCC; microarrays; neoadjuvant

Indexed keywords

CYCLIN DEPENDENT KINASE 2; ERLOTINIB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MODIFIER GENE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GLUCURONOSYLTRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84878018022     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23036     Document Type: Article

References (34)

1. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
2. Herbst RS, Langer CJ,. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29 (1 Suppl 4): 27-36.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N,. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
4. Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 78: 696-702.
5. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
6. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
7. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
8. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
9. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
10. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25: 2184-2190.
11. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 7086-7092.
12. Benjamini Y, Hochberg Y,. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
13. Thomas F, Rochaix P, White-Koning M, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009; 45: 2316-2323.
14. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006; 34: 420-426.
15. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 261-270.
16. Chin D, Boyle GM, Williams RM, et al. Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 2005; 115: 1239-1242.
17. Kamradt MC, Lu M, Werner ME, et al. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 2005; 280: 11059-11066.
18. Mao YW, Liu JP, Xiang H, Li DW,. Human alphaA- and alphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ 2004; 11: 512-526.
19. Ree AH, Tvermyr M, Engebraaten O, et al. Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res 1999; 59: 4675-4680.
20. Giroux V, Malicet C, Barthet M, et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 2006; 12: 235-241.
21. Clark DW, Mitra A, Fillmore RA, et al. NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets 2008; 8: 421-430.
22. Cangul H,. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004; 5: 27.
23. Denko N, Schindler C, Koong A, Laderoute K, Green C, Giaccia A,. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000; 6: 480-487.
24. Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J,. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 2005; 24: 1138-1149.
25. Cerniglia GJ, Pore N, Tsai JH, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009; 4: e6539.
26. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A,. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197-3204.
27. Freier K, Sticht C, Hofele C, et al. Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer 2006; 45: 118-125.
28. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD,. Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996; 12: 31-35.
29. Rodrigo JP, García LA, Ramos S, Lazo PS, Suárez C,. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6: 3177-3182.
30. Clark ES, Whigham AS, Yarbrough WG, Weaver AM,. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007; 67: 4227-4235.
31. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ,. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007; 67: 9304-9314.
32. Mascia F, Mariani V, Girolomoni G, Pastore S,. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-312.
33. Grishina I, Lattes B,. A novel Cdk2 interactor is phosphorylated by Cdc7 and associates with components of the replication complexes. Cell Cycle 2005; 4: 1120-1126.
34. Lovejoy CA, Xu X, Bansbach CE, et al. Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A 2009; 106: 19304-19309.